OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EKAD$171.0056

Ekadharma International Tbk PT

Specialty ChemicalsVerified

Ekadharma International Tbk PT maintains a strong liquidity position, with a current ratio of 13.88, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 101,933,403,180 IDR, which is a substantial portion of its total assets. The price-to-book ratio of 0.53 suggests that the company is trading at a discount to its book value, potentially indicating undervaluation or asset-heavy operations. In terms of profitability, Ekadharma's return on equity (ROE) is 2.16%, and its return on assets (ROA) is 1.92%. These figures are below the typical thresholds for high-performing specialty chemical firms, suggesting that the company may not be generating returns as efficiently as its peers. The company's gross profit margin is 32.07%, and its operating margin is 21.74%, which are in line with industry norms but do not indicate exceptional performance. The company's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic fluctuations and regulatory changes. The company's revenue for the latest period is 123,884,573,220 IDR, and while there is no specific growth trajectory provided, the company's operating cash flow of 29,934,007,920 IDR suggests a stable cash-generating business. Ekadharma's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.02, which is very low and suggests a conservative capital structure with minimal leverage. The company has not issued any new shares recently, and there are no indications of near-term dilution pressure. Recent financial filings and transcripts do not highlight any significant events or strategic shifts. The company's latest actual revenue of 643,591,820,000 IDR is lower than the reported revenue of 123,884,573,220 IDR, which may indicate a discrepancy in reporting periods or a need for further clarification. The company's capital expenditure of -5,929,932,100 IDR suggests a reduction in capital spending, which could be a strategic move to preserve cash or a sign of reduced investment in growth initiatives.

30-day price · EKAD-4.00 (-2.2%)
Low$175.00High$185.00Close$175.00As of13 May, 00:00 UTC
Profile
CompanyEkadharma International Tbk PT
TickerEKAD.JK
SectorBasic Materials
BusinessChemicals
Industry groupChemicals
IndustrySpecialty Chemicals
AI analysis

Business. Ekadharma International Tbk PT is a specialty chemicals company that produces and distributes chemical products, primarily serving industrial and commercial clients.

Classification. Ekadharma is classified under the Basic Materials economic sector, Chemicals business sector, and Specialty Chemicals industry with a confidence level of 0.92.

Ekadharma International Tbk PT maintains a strong liquidity position, with a current ratio of 13.88, indicating a significant buffer of current assets relative to current liabilities. The company's cash and equivalents amount to 101,933,403,180 IDR, which is a substantial portion of its total assets. The price-to-book ratio of 0.53 suggests that the company is trading at a discount to its book value, potentially indicating undervaluation or asset-heavy operations. In terms of profitability, Ekadharma's return on equity (ROE) is 2.16%, and its return on assets (ROA) is 1.92%. These figures are below the typical thresholds for high-performing specialty chemical firms, suggesting that the company may not be generating returns as efficiently as its peers. The company's gross profit margin is 32.07%, and its operating margin is 21.74%, which are in line with industry norms but do not indicate exceptional performance. The company's revenue is concentrated in a single business segment, as disclosed in its financial reports, with no material geographic diversification reported. This lack of diversification could expose the company to regional economic fluctuations and regulatory changes. The company's revenue for the latest period is 123,884,573,220 IDR, and while there is no specific growth trajectory provided, the company's operating cash flow of 29,934,007,920 IDR suggests a stable cash-generating business. Ekadharma's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.02, which is very low and suggests a conservative capital structure with minimal leverage. The company has not issued any new shares recently, and there are no indications of near-term dilution pressure. Recent financial filings and transcripts do not highlight any significant events or strategic shifts. The company's latest actual revenue of 643,591,820,000 IDR is lower than the reported revenue of 123,884,573,220 IDR, which may indicate a discrepancy in reporting periods or a need for further clarification. The company's capital expenditure of -5,929,932,100 IDR suggests a reduction in capital spending, which could be a strategic move to preserve cash or a sign of reduced investment in growth initiatives.
Key takeaways
  • Ekadharma International Tbk PT has a strong liquidity position with a high current ratio and significant cash reserves.
  • The company's profitability metrics, including ROE and ROA, are below industry benchmarks, indicating room for improvement in operational efficiency.
  • The company's revenue is concentrated in a single business segment, which could increase exposure to sector-specific risks.
  • Ekadharma maintains a conservative capital structure with minimal debt and no immediate dilution risks.
  • The company's recent capital expenditure is negative, suggesting a strategic shift or reduced investment in growth.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue$123.88B
Gross profit$39.73B
Operating income$26.94B
Net income$24.23B
R&D
SG&A
D&A
SBC
Operating cash flow$29.93B
CapEx-$5.93B
Free cash flow$27.77B
Total assets$1.26T
Total liabilities$138.63B
Total equity$1.12T
Cash & equivalents$101.93B
Long-term debt$26.69B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$629.88B$132.04B$104.41B$88.41B
FY-3$614.48B$93.02B$76.72B$54.53B
FY-2$518.36B$77.64B$71.94B$45.87B
FY-1$530.43B$65.55B$64.44B$36.87B
FY0$529.53B$46.88B$53.02B$25.10B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.17T$998.24B$360.66B
FY-3$1.22T$1.08T$392.55B
FY-2$1.25T$1.11T$126.64B
FY-1$1.29T$1.16T$18.07B
FY0$1.37T$1.23T$23.42B
PeriodOCFCapExFCFSBC
FY-4$46.05B-$12.51B$88.41B
FY-3$96.21B-$9.25B$54.53B
FY-2$92.50B-$17.35B$45.87B
FY-1$53.97B-$16.46B$36.87B
FY0$101.63B-$18.52B$25.10B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$123.88B$26.94B$24.23B$27.77B
FQ-6$141.71B$24.32B$21.97B$17.92B
FQ-5$134.37B-$1.09B$973.7M$3.64B
FQ-4$128.58B$5.92B$7.21B$5.67B
FQ-3$123.31B$13.46B$14.41B$12.77B
FQ-2$141.22B$9.63B$8.92B$8.62B
FQ-1$136.42B$17.87B$22.48B$28.87B
FQ0$142.34B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.26T$1.12T$101.93B
FQ-6$1.30T$1.16T$83.46B
FQ-5$1.29T$1.16T$18.07B
FQ-4$1.31T$1.17T$2.05B
FQ-3$1.29T$1.16T$2.46B
FQ-2$1.31T$1.18T$2.91B
FQ-1$1.37T$1.23T$23.42B
FQ0$1.23T$91.40B
PeriodOCFCapExFCFSBC
FQ-7$29.93B-$5.93B$27.77B
FQ-6$33.55B-$14.40B$17.92B
FQ-5$53.97B-$16.46B$3.64B
FQ-4$12.48B-$7.02B$5.67B
FQ-3$41.73B-$13.55B$12.77B
FQ-2$77.13B-$19.69B$8.62B
FQ-1$101.63B-$18.52B$28.87B
FQ0$11.10B-$3.35B
Valuation
Market price$171.00
Market cap$597.45B
Enterprise value$522.21B
P/E24.6
Reported non-GAAP P/E
EV/Revenue4.2
EV/Op income19.4
EV/OCF17.4
P/B0.5
P/Tangible book0.5
Tangible book$1.12T
Net cash$75.24B
Current ratio13.9
Debt/Equity0.0
ROA1.9%
ROE2.2%
Cash conversion1.2%
CapEx/Revenue-4.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Chemicals · cohort 1439 companies
MetricEKADActivity
Op margin21.7%5.5% medp25 -0.0% · p75 10.8%top quartile
Net margin19.6%4.1% medp25 0.1% · p75 8.8%top quartile
Gross margin32.1%20.5% medp25 12.4% · p75 29.7%top quartile
R&D / revenue1.5% medp25 1.0% · p75 2.1%
CapEx / revenue-4.8%-6.2% medp25 -13.4% · p75 -2.6%above median
Debt / equity2.0%37.1% medp25 10.3% · p75 82.0%bottom quartile
Observations
IR observations
Last actual revenue643,591,820,000 IDR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 04:46 UTC#2272dc8c
Market quoteclose IDR 179.00 · shares 3.49B diluted
no public URL
2026-05-09 04:46 UTC#d425e5fd
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 20:26 UTCJob: 7bfae0c3